Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of UI068 (Linagliptin + Metformin) in Healthy Volunteers
NCT06141590Phase 1Completed
- Sponsor
- Korea United Pharm Inc.
- Start
- Mar 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of linagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Korea United Pharm Inc. Primary endpoints: Area Under the Concentration-Time Curve from time 0 to the last measurable concentration and Maximum Plasma Concentration. Started Mar 2023; status: completed.
02
Drugs
linagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06141590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06141590.